Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait
Abrilada May Launch From Late 2023 Under A Settlement With AbbVie
Pfizer has secured FDA approval for its adalimumab biosimilar under the name Abrilada, representing the agency’s 25th biosimilar approval overall. However, patent settlements around the Humira brand mean that Pfizer is not due to enter the market for four years.
You may also be interested in...
While the latest IQVIA data points to accelerated uptake of US biosimilars over the next five years, with associated increases in spending and savings, local off-patent industry association the AAM says the report raises a “red flag” over long-term market sustainability.
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.